^
    Back
    Association details:
    Biomarker:BRCA1 mutation
    Cancer:Germ Cell Tumors
    Drug:Lynparza (olaparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Pancreatic Cancer)
    New
    Title:

    Lynparza approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers

    Excerpt:
    AstraZeneca and MSD’s Lynparza (olaparib) has been approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers….The three approvals authorise Lynparza for:...maintenance treatment after platinum-based chemotherapy for patients with BRCAm curatively unresectable pancreas cancer.
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ASCO 2020
    Title:

    Olaparib as salvage treatment for advanced germ cell tumors after chemotherapy failure: Results of the open-label, single-arm, IGG-02 phase II trial

    Excerpt:
    The 12-week progression-free survival probability was 27.8% [95% confidence interval (CI): 10.1%-48.9%]. The 12-month overall survival probability was 27.8% (95% CI: 10.1%-48.9%). A germline DNA repair profile panel showed only a BRCA1 mutated case associated with a SD lasted 4 months.
    DOI:
    10.1200/JCO.2020.38.15_suppl.5058
    Trial ID:
    NCT02533765
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Mol Oncol
    Title:

    Promoter methylation of DNA homologous recombination genes is predictive of the responsiveness to PARP inhibitor treatment in testicular germ cell tumors

    Published date:
    01/01/2021
    Excerpt:
    CONTRADICTING EVIDENCE:...we demonstrated the sensitivity of TGCT cell lines to Olaparib, which associated with differential methylation levels of a subset of targets, namely BRCA1 and RAD51C...the cell line least responsive to Olaparib (TCam-2) presented the highest BRCA1 and RAD51C expression levels.
    DOI:
    10.1002/1878-0261.12909